Sesen Bio Receives Delisting Notice, Emphasizing Need for Merger with Carisma Therapeutics to Avoid Deregistration.
January 31, 2023
Trending News 🌧️
Sesen Bio ($NASDAQ:SESN), a biopharmaceutical company focused on developing novel targeted therapies to treat cancer, recently received a delisting notice from Nasdaq. The notice came as a result of the company’s share price falling below $1, which is the minimum requirement for continued listing on the exchange. The delisting notice highlights the urgent need for the merger between Sesen Bio and Carisma Therapeutics to be completed. If the merger is not completed, then Sesen Bio’s stock will be deregistered and the company will be subject to a court-ordered dissolution and liquidation process. The merger is expected to increase Sesen Bio’s presence in the cancer therapy market, as Carisma Therapeutics has a strong presence in the development of antibody-drug conjugates. Carisma Therapeutics also has a number of promising assets in their pipeline, including an ADC technology that is expected to be a “game changer” in the field of cancer therapy.
The proposed merger between Sesen Bio and Carisma Therapeutics is currently under review by the U.S. Federal Trade Commission. Sesen Bio has stated that they are confident in the success of the merger, and are working hard to ensure that it goes ahead as planned. The delisting notice from Nasdaq serves as a reminder of the importance of completing the merger in order for Sesen Bio to remain listed on Nasdaq. The company’s future depends on it, and it is essential that all parties involved work together to ensure that the merger goes ahead as soon as possible.
Market Price
On Monday, SESEN BIO, a biopharmaceutical company, received a delisting notice from Nasdaq. In response to the delisting notice, SESEN BIO’s stock opened at $0.6 and closed at $0.6, down by 3.3% from a previous closing price of 0.6. The merger between SESEN BIO and Carisma Therapeutics would create a unique organization that combines the two companies’ extensive experience in developing and commercializing novel gene therapy treatments. This would allow the combined company to capitalize on the strengths of both companies and advance their clinical pipeline to address unmet medical needs.
The merger between SESEN BIO and Carisma Therapeutics is expected to create a powerful platform for the development of gene therapies across multiple therapeutic areas with significant potential for long-term value creation. It is hoped that this merger will help SESEN BIO meet its goal of becoming a leader in gene therapy and significantly improve its chances of avoiding deregistration. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sesen Bio. More…
| Total Revenues | Net Income | Net Margin |
| 60 | -3.37 | -23.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sesen Bio. More…
| Operations | Investing | Financing |
| 9.61 | -113.73 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sesen Bio. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 199.72 | 34.7 | 0.81 |
Key Ratios Snapshot
Some of the financial key ratios for Sesen Bio are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 197.9% | – | -43.3% |
| FCF Margin | ROE | ROA |
| 16.0% | -10.6% | -8.1% |
VI Analysis
Investors looking to evaluate the long-term potential of SESEN BIO should take advantage of the VI App, which makes it easy to analyze the company’s fundamentals. According to the VI Risk Rating, SESEN BIO is considered a high risk investment in terms of both financial and business aspects. The app has detected four risk warnings in SESEN BIO’s income sheet, balance sheet, cashflow statement, and financial journal. Those who want to get a closer look at the company’s risk factors must become a registered user and access the detailed information. SESEN BIO’s income sheet reveals that its total revenues are increasing over time, but its gross profit margin has decreased since last year. The balance sheet shows that the company’s total liabilities are higher than its total assets. This means that it has more debts than it can cover with its assets. The cashflow statement indicates that the company is having difficulty generating enough cash to cover its operating and investing expenses. Finally, the financial journal shows that the company’s earnings have been declining since last year. Overall, SESEN BIO is a high risk investment that should be carefully evaluated before investing in. The VI App provides an easy way to analyze the company’s fundamentals and uncover important risk factors. Registered users can access more detailed information about the company’s financial health and risks. More…
VI Peers
The healthcare sector is competitive, and companies are always vying for market share. Sesen Bio Inc is no different, and it competes against Gossamer Bio Inc, Galmed Pharmaceuticals Ltd, and ARCA biopharma Inc. in the development and commercialization of treatments for cancer and other diseases. While each company has its own strengths and weaknesses, Sesen Bio Inc has proven to be a formidable competitor.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of immunology, inflammation and oncology. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
As of 2022, Gossamer Bio has a market cap of 1.17B and a ROE of -3124.66%. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
– Galmed Pharmaceuticals Ltd ($NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic solutions targeting liver diseases. The company’s lead product candidate, Aramchol, is a once-daily, oral treatment for non-alcoholic steatohepatitis (NASH). Galmed is planning to initiate a Phase III clinical trial for Aramchol in 2020. The company has a market cap of 9.04M as of 2022 and a Return on Equity of -111.62%.
– ARCA biopharma Inc ($NASDAQ:ABIO)
ACRA biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of cancer and other diseases. The company has a market cap of 29.54M as of 2022 and a Return on Equity of -22.71%. ACRA biopharma Inc was founded in 2006 and is headquartered in San Diego, CA.
Summary
Sesen Bio is a biopharmaceutical company that has recently received a delisting notice from the Nasdaq, which has caused its stock price to decline sharply. This notice emphasizes the need for the company to merge with Carisma Therapeutics in order to avoid deregistration. Investors should be cautious when conducting analysis on Sesen Bio, as its future is uncertain.
The merger with Carisma Therapeutics could bring greater stability, but there is no guarantee that the deal will go through. Investors should keep a close eye on the stock, as any developments regarding this merger could have an impact on Sesen Bio’s stock price.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
